Page 149 - Human Use News Today

Investegate announcements from BioNTech SE, BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Fourth quarter and full year revenues of €5.5 billion1 and €19.0 billion1, respectivelyFull year net income of €10.3 billion and fully diluted earnings per share of €39.63 ($46.872)Expect to authorize

Create a system based on connectivity and automation, aggregated and usable data, flexible analysis, and methods of collaborative data review by...

29.03.2022 - Orphazyme A/S in restructuringCompany announcementNo. 14/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 29, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage ...

The March meeting saw the CHMP recommend five medications for approval including a multiple myeloma gene therapy.

Exploring the complexities of nitrosamines to enhance understanding and overall management, with a focus on nitrosamine drug substance-related impurities (NDSRIs).

Chisinau, Moldova (PRWEB) March 26, 2022 -- Book has 4 chapters each of which can be read on its own with a common underlying theme giving an

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Polivy in combination with

Ciltacabtagene autoleucel (cilta-cel), Janssen's first cell therapy, is a structurally differentiated CAR-T with two BCMA-targeting single domain antibodies The Janssen Pharmaceutical Companies of Johnson

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Commission (EC) has expanded the current indication for...